VALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Subjects who the investigator believes that they   │ Subjects who the investigator believes that they   │     100 │
│ can and will comply with the requirements of the   │ can and will comply with the requirements of the   │         │
│ protocol should be enrolled in the study           │ protocol should be enrolled in the study           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ A male or female aged 61 years or above at the     │ A male or female aged 61 years or above at the     │     100 │
│ time of the first vaccination                      │ time of the first vaccination                      │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Written informed consent obtained from the subject │ Written informed consent obtained from the subject │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Healthy subjects or subjects with well controlled  │ Healthy subjects or subjects with well controlled  │     100 │
│ underlying disease                                 │ underlying disease                                 │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Administration of the licensed MF59-containing     │ Administration of the licensed MF59-containing     │     100 │
│ vaccines, e.g. Fluad™ or Addigrip™ or virosome-    │ vaccines, e.g. Fluad™ or Addigrip™ or virosome-    │         │
│ based influenza vaccines such as Inflexal V™,      │ based influenza vaccines such as Inflexal V™,      │         │
│ InfectoVac Flu™ or Invivac™ during the 2006-2007   │ InfectoVac Flu™ or Invivac™ during the 2006-2007   │         │
│ influenza season                                   │ influenza season                                   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Administration of licensed vaccines within 2 weeks │ Administration of licensed vaccines within 2 weeks │     100 │
│ (for inactivated vaccines) or 4 weeks (for live    │ (for inactivated vaccines) or 4 weeks (for live    │         │
│ vaccines) prior to enrolment in this study         │ vaccines) prior to enrolment in this study         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Planned administration of a vaccine not foreseen   │ Planned administration of a vaccine not foreseen   │     100 │
│ by the study protocol up to 30 days after the      │ by the study protocol up to 30 days after the      │         │
│ second vaccination with H5N1 vaccine               │ second vaccination with H5N1 vaccine               │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Chronic administration (defined as more than 14    │ Chronic administration (defined as more than 14    │     100 │
│ days) of immunosuppressants or other immune-       │ days) of immunosuppressants or other immune-       │         │
│ modifying drugs within six months prior to the     │ modifying drugs within six months prior to the     │         │
│ first administration of the study vaccine          │ first administration of the study vaccine          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Any confirmed or suspected immunosuppressive or    │ Any confirmed or suspected immunosuppressive or    │     100 │
│ immunodeficient condition, based on medical        │ immunodeficient condition, based on medical        │         │
│ history and physical examination (no laboratory    │ history and physical examination (no laboratory    │         │
│ testing required)                                  │ testing required)                                  │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ History of chronic alcohol consumption and/or drug │ History of chronic alcohol consumption and/or drug │     100 │
│ abuse                                              │ abuse                                              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ History of hypersensitivity to vaccines            │ History of hypersensitivity to vaccines            │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ History of allergic disease or reactions likely to │ History of allergic disease or reactions likely to │     100 │
│ be exacerbated by any component of the vaccine     │ be exacerbated by any component of the vaccine     │         │
│ (including egg and thiomersal allergy)             │ (including egg and thiomersal allergy)             │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Acute clinically significant pulmonary,            │ Acute clinically significant pulmonary,            │     100 │
│ cardiovascular, hepatic or renal functional        │ cardiovascular, hepatic or renal functional        │         │
│ abnormality, as determined by physical examination │ abnormality, as determined by physical examination │         │
│ or laboratory screening tests                      │ or laboratory screening tests                      │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Acute disease at the time of enrolment             │ Acute disease at the time of enrolment             │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Serious chronic disease including any medically    │ Serious chronic disease including any medically    │     100 │
│ significant chronic pulmonary, cardiovascular,     │ significant chronic pulmonary, cardiovascular,     │         │
│ renal, neurological, psychiatric or metabolic      │ renal, neurological, psychiatric or metabolic      │         │
│ disorder, as determined by medical history and     │ disorder, as determined by medical history and     │         │
│ physical examination                               │ physical examination                               │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Administration of immunoglobulins and/or any blood │ Administration of immunoglobulins and/or any blood │     100 │
│ products within the three months preceding the     │ products within the three months preceding the     │         │
│ first vaccination or during the study              │ first vaccination or during the study              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Use of any investigational or non-registered       │ Use of any investigational or non-registered       │     100 │
│ product (drug or vaccine) other than the study     │ product (drug or vaccine) other than the study     │         │
│ vaccine(s) within 30 days prior to the first       │ vaccine(s) within 30 days prior to the first       │         │
│ vaccination, or planned use during the study       │ vaccination, or planned use during the study       │         │
│ period                                             │ period                                             │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Any condition which, in the opinion of the         │ Any condition which, in the opinion of the         │     100 │
│ investigator, prevents the subject from            │ investigator, prevents the subject from            │         │
│ participation in the study                         │ participation in the study                         │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒═══════════════════════════════════╤════════════════════════════════════════╤═════════╕
│ Personal Criteria                 │ CHIA Criteria                          │   Score │
╞═══════════════════════════════════╪════════════════════════════════════════╪═════════╡
│ Must have minimum age of 60 Years │ Acute disease at the time of enrolment │      45 │
╘═══════════════════════════════════╧════════════════════════════════════════╧═════════╛

CHIA has no unique criteria

Levenshtein Ratio of Entire trial at once: 99
Average Levenshtein Ratio of individual lines: 97.10526315789474
OverAll Ratio: 98.05263157894737
